Cigna (CI) Downgraded by Barclays, Price Target Cut to $304
Published on Β· Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowOn May 26, Barclays downgraded Cigna (CI) from Overweight to Equal Weight and reduced its price target from $310 to $304. The downgrade reflects concerns around Cigna's limited earnings upside potential due to its lower exposure to government insurance programs, alongside uncertainties regarding a pharmacy benefit manager transition. Additionally, Barclays highlighted risks related to commercial membership losses and potential job cuts related to AI. This situation contrasts with UBS's recent rating increase, raising Cigna's target to $400, indicating differing outlooks among analysts.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About The Cigna Group (CI)
The Cigna Group is a major U.S. health-insurance and pharmacy-benefits company.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier CI news
- Cigna (CI) Q1 2026 Earnings Beat Expectations; Raises EPS Guidance
- CI&T Inc (CINT) Q4 2025 Revenue Increases 19.3% to $134 Million
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
